Investors
Invest in InDex
Pharmaceuticals
-
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2022
August 26, 2022 Regulatory
-
InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan
August 16, 2022 Non Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q2 for January-June 2022 on August 26, 2022 at 08:00 a.m. CEST.
-
Presentation at Redeye investor AW in Gothenburg
-
Interim Report Q3 2022
-
Year-end Report 2022
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
7.5 billion USD
Total yearly sales of medications for ulcerative colitis
-
12 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2026
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
